Clinical Trial Update: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating allogeneic mesenchymal bone marrow cells for ST-elevation myocardial infarction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• Allogeneic Mesenchymal Bone Marrow Cells (mesenchymal stem cells)

Snippet

Sponsor: Stemedica Cell Technologies, Inc. | Conditions: ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells | Phase 2 | Status: WITHDRAWN